Literature DB >> 15570264

Life-style modification in peripheral arterial disease.

S Khan1, M Cleanthis, J Smout, M Flather, G Stansby.   

Abstract

OBJECTIVE: To review the published evidence supporting the use of life-style modification in peripheral arterial disease (PAD).
DESIGN: A systematic search of the medical literature was performed for relevant studies. MATERIALS: The publications obtained were then searched for randomised clinical trials which reported end-points of mortality or major cardiovascular event rates with various life-style modifications.
RESULTS: Only one randomised controlled trial was found reporting relevant end-points. Other trials were of other end-points such as walking distance or biochemical markers.
CONCLUSIONS: There is a lack of randomised controlled data proving the benefit of life-style modification in improving mortality and reducing cardiovascular events in patients with PAD. Despite this there is sufficient evidence to recommend some life-style modification as part of the overall approach to risk reduction in these patients. There is compelling evidence to support smoking cessation, increased exercise and improved diet.

Entities:  

Mesh:

Year:  2005        PMID: 15570264     DOI: 10.1016/j.ejvs.2004.09.020

Source DB:  PubMed          Journal:  Eur J Vasc Endovasc Surg        ISSN: 1078-5884            Impact factor:   7.069


  8 in total

1.  Statin-associated muscle-related adverse effects: a case series of 354 patients.

Authors:  Stephanie Cham; Marcella A Evans; Julie O Denenberg; Beatrice A Golomb
Journal:  Pharmacotherapy       Date:  2010-06       Impact factor: 4.705

Review 2.  Cilostazol for intermittent claudication.

Authors:  Rachel Bedenis; Marlene Stewart; Marcus Cleanthis; Peter Robless; Dimitri P Mikhailidis; Gerard Stansby
Journal:  Cochrane Database Syst Rev       Date:  2014-10-31

3.  Increasing walking in patients with intermittent claudication: protocol for a randomised controlled trial.

Authors:  Maggie A Cunningham; Vivien Swanson; Ronan E O'Carroll; Richard J Holdsworth
Journal:  BMC Cardiovasc Disord       Date:  2010-10-07       Impact factor: 2.298

4.  Safety of cilostazol in peripheral artery disease: a cohort from a primary healthcare electronic database.

Authors:  Jordi Real; M Catalina Serna; Maria Giner-Soriano; Rosa Forés; Guillem Pera; Esther Ribes; Maite Alzamora; Josep Ramon Marsal; Antonio Heras; Rosa Morros
Journal:  BMC Cardiovasc Disord       Date:  2018-05-08       Impact factor: 2.298

5.  Increased cold injuries and the effect of body mass index in patients with peripheral vascular disease.

Authors:  Jin-Young Min; Yeon-Soo Choi; Hyeong-Seong Lee; Sohyae Lee; Kyoung-Bok Min
Journal:  BMC Public Health       Date:  2021-02-05       Impact factor: 3.295

6.  Three-year follow-up and event rates in the international REduction of Atherothrombosis for Continued Health Registry.

Authors:  Mark J Alberts; Deepak L Bhatt; Jean-Louis Mas; E Magnus Ohman; Alan T Hirsch; Joachim Röther; Geneviève Salette; Shinya Goto; Sidney C Smith; Chiau-Suong Liau; Peter W F Wilson; Ph Gabriel Steg
Journal:  Eur Heart J       Date:  2009-08-31       Impact factor: 29.983

7.  Long-term survival after initial hospital admission for peripheral arterial disease in the lower extremities.

Authors:  I Vaartjes; G J de Borst; J B Reitsma; A de Bruin; F L Moll; D E Grobbee; M L Bots
Journal:  BMC Cardiovasc Disord       Date:  2009-08-28       Impact factor: 2.298

8.  Cilostazol for intermittent claudication.

Authors:  Tamara Brown; Rachel B Forster; Marcus Cleanthis; Dimitri P Mikhailidis; Gerard Stansby; Marlene Stewart
Journal:  Cochrane Database Syst Rev       Date:  2021-06-30
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.